BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 28356514)

  • 1. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
    Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
    Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.
    Parkhi M; Bal A; Das A; Kashyap D; Bhardwaj S; Prakash G; Malhotra P
    Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):648-656. PubMed ID: 33901030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O
    Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
    Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
    Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
    Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
    Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.
    Wang JC; Zhong LH; Lin WQ; Zhang WF; Xi YF; Liu YP; Zhu Q; Liu W; Zhu WF; Chen YP; Chen G
    Am J Surg Pathol; 2023 Jan; 47(1):55-64. PubMed ID: 36315833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
    Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
    Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
    Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
    Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
    Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
    Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.